TGFB1 gene polymorphism Leu10Pro (c.29T>C), prostate cancer incidence and quality of life in patients treated with brachytherapy

World Journal of Urology

Volumn 27, Issue 3, 2009, Pages 371-377

  Meyer, Andreas ^a   Dörk, Thilo ^a   Bogdanova, Natalia ^a   Brinkhaus, Maria Jantje ^a   Wiese, Birgitt ^a   Hagemann, Jörn ^a   Serth, Jürgen ^a   Bremer, Michael ^a   Baumann, Rolf ^a   Karstens, Johann H ^a   Machtens, Stefan ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Marien Krankenhaus Bergisch Gladbach   (Germany)

Author keywords

Brachytherapy; Late effects; Prostate cancer; TGFB1 gene polymorphism

Indexed keywords

TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA1;

AGED; ARTICLE; BRACHYTHERAPY; GENETIC POLYMORPHISM; GENETICS; HUMAN; INCIDENCE; MALE; MIDDLE AGED; PROSTATE TUMOR; QUALITY OF LIFE;

AGED; BRACHYTHERAPY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TRANSFORMING GROWTH FACTOR BETA1;

EID: 67349284341     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-008-0354-0     Document Type: Article

References (30)

1. Gsur A, Feik E, Madersbacher S (2004) Genetic polymorphisms and prostate cancer risk. World J Urol 21:414-423. doi: 10.1007/s00345-003-0378-4
2. Fan R, Kumaravel TS, Jalali F, Marrano P, Squire JA, Bristow RG (2004) Defective DNA strand break repair after DNA damage in prostate cancer cells: Implications for genetic instability and prostate cancer progression. Cancer Res 64:8526-8533. doi: 10.1158/0008-5472.CAN-04-1601
3. Derynck R, Akhurst RJ, Balmain A (2001) TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29:117-129. doi: 10.1038/ ng1001-117
4. Ravitz MJ, Wenner CE (1997) Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-beta. Adv Cancer Res 71:165-207. doi: 10.1016/S0065-230X(08)60099-8
5. Wikstrom P, Damber J-E, Bergh A (2001) Role of transforming growth factor-b1 in prostate cancer. Microsc Res Tech 52:411-419. doi:10.1002/ 1097-0029(20010215)52:4<;411::AID-JEMT1026>;3.0.CO;2-8
6. Barrack ER (1997) TGFβ in prostate cancer: A growth inhibitor that can enhance tumorigenicity. Prostate 31:61-70. doi:10.1002/ (SICI)1097-0045(19970401)31:1<;61::AID-PROS10>;3.0.CO;2-M
7. Meyer A, Wilhelm B, Dörk T, Bremer M, Baumann R, Karstens JH, Machtens S (2007) ATM missense variant P1054R predisposes to prostate cancer. Radiother Oncol 83:283-288. doi: 10.1016/j.radonc.2007.04.029
8. Kirshner J, Jobling MF, Pajares MJ, Ravani SA, Glick AB, Lavin MJ, Koslov S, Shiloh Y, Barcellos-Hoff MH (2006) Inhibition of transforming growth factor-beta1 signaling attenuates ataxia telangiectasia mutated activity in response to genotoxic stress. Cancer Res 66:10861-10869. doi: 10.1158/0008-5472.CAN-06-2565
9. Guo Y, Kyprianou N (1999) Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Cancer Res 59:1366-1371
10. Cambien F, Ricard S, Troesch A, Mallet C, Générénaz L, Evans A, Arveiler D, Luc G, Ruidavets JB, Poirier O (1996) Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Temoin de l'Infarctus du Myocarde (ECTIM) Study. Hypertension 28:881-887
11. Randall LL, Hardy SJ (1989) Unity in function in the absence of consensus in sequence: Role of leader peptides in export. Science 243:1156-1159. doi: 10.1126/science.2646712
12. Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, Kemp PR, Luben RN, Chang-Claude J, Mannermaa A, Kataja V, Pharoah PD, Easton DF, Ponder BA, Metcalfe JC (2003) A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 63:2610-2615
13. Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, Carter ND, Spector TD (1999) Genetic control of the circulating concentration of transforming growth factor type β1. Hum Mol Genet 8:93-97. doi: 10.1093/hmg/8.1.93
14. Suthanthiran M, Li B, Song JO, Ding R, Sharma VK, Schwartz JE, August P (2000) Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci USA 97:3479-3484. doi: 10.1073/ pnas.050420897
15. Li Z, Habuchi T, Tsuchiya N, Mitsumori K, Wang L, Ohyama C, Sato K, Kamoto T, Ogawa O, Kato T (2004) Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10. Carcinogenesis 25:237-240. doi: 10.1093/carcin/bgg197
16. Ewart-Toland A, Chan JM, Yuan J, Balmain A, Ma J (2004) A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer. Cancer Epidemiol Biomarkers Prev 13:759-764
17. Kang D, Lee KM, Park SK, Berndt SI, Reding D, Chatterjee N, Welch R, Chanock S, Huang WY, Hayes RB (2007) Lack of association of transforming growth factor-beta1 polymorphisms and TGFB1 genotypes with prostate cancer risk in the prostate, lung, colorectal, and ovarian trial. Cancer Epidemiol Biomarkers Prev 16:1303-1305. doi: 10.1158/ 1055-9965.EPI-06-0895
18. Machtens S, Baumann R, Hagemann J, Warszawski A, Meyer A, Karstens JH, Jonas U (2006) Long-term results of interstitial brachytherapy (LDR-Brachytherapy) in the treatment of patients with prostate cancer. World J Urol 24:289-295. doi: 10.1007/s00345-006-0083-1
19. Norderhaug I, Dahl O, Hoisaeter PA, Heikkiä R, Klepp O, Olsen DR, Kristiansen IS, Waehre H, Bjerklund Johansen TE (2003) Brachytherapy for prostate cancer: A systematic review of clinical and cost effectiveness. Eur Urol 44:40-46. doi: 10.1016/S0302-2838(03)00187-8
20. Finkelstein JN, Johnston CJ, Baggs R, Rubin P (1994) Early alterations in extracellular matrix and transforming growth factor beta gene expression in mouse lung indicative of late radiation fibrosis. Int J Radiat Oncol Biol Phys 28:621-631
21. De Ruyck K, Van Eijkeren M, Claes K, Bacher K, Vral A, De Neve W, Thierens H (2006) TGFbeta1 polymorphisms and late clinical radiosensitivity in patients treated for gynecologic tumors. Int J Radiat Oncol Biol Phys 65:1240-1248. doi: 10.1016/j.ijrobp.2006.03.047
22. Peters CA, Stock RG, Cesaretti JA, Atencio DP, Peters S, Burri RJ, Stone NN, Ostrer H, Rosenstein BS (2008) TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 70:752-759. doi: 10.1016/j.ijrobp.2007.05.023
23. Dupont WD, Plummer WD (1997) PS power and sample size program available for free on the Internet. Control Clin Trials 18:274. doi: 10.1016/ S0197-2456(97)00074-3
24. Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, Reed MW, Pooley KA, Scollen S, Baynes C, Ponder BA, Chanock S, Lissowska J, Brinton L, Peplonska B, Southey MC, Hopper JL, McCredie MR, Giles GG, Fletcher O, Johnson N, dos Santos Silva I, Gibson L, Bojesen SE, Nordestgaard BG, Axelsson CK, Torres D, Hamann U, Justenhoven C, Brauch H, Chang-Claude J, Kropp S, Risch A, Wang-Gohrke S, Schürmann P, Bogdanova N, Dörk T, Fagerholm R, Aaltonen K, Blomqvist C, Nevanlinna H, Seal S, Renwick A, Stratton MR, Rahman N, Sangrajrang S, Hughes D, Odefrey F, Brennan P, Spurdle AB, Chenevix-Trench G, Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer, Beesley J, Mannermaa A, Hartikainen J, Kataja V, Kosma VM, Couch FJ, Olson JE, Goode EL, Broeks A, Schmidt MK, Hogervorst FB, Van't Veer LJ, Kang D, Yoo KY, Noh DY, Ahn SH, Wedrén S, Hall P, Low YL, Liu J, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Sigurdson AJ, Stredrick DL, Alexander BH, Struewing JP, Pharoah PD, Easton DF, Breast Cancer Association Consortium (2007) A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 39:352-358. doi: 10.1038/ ng1981
25. Andreassen CN, Alsner J, Overgaard J, Herskind C, Haviland J, Owen R, Homewood J, Bliss J, Yarnold J (2005) TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother Oncol 75:18-21. doi: 10.1016/j.radonc.2004.12.012
26. Quarmby S, Fakhoury H, Levine E, Barber J, Wylie J, Hajeer AH, West C, Stewart A, Magee B, Kumar S (2003) Association of transforming growth factor beta-1 single nucleotide polymorphisms with radiation-induced damage to normal tissues in breast cancer patients. Int J Radiat Biol 79:137-143. doi: 10.1080/713865032
27. Andreassen CN, Alsner J, Overgaard M, Sørensen FB, Overgaard J (2006) Risk of radiation-induced subcutaneous fibrosis in relation to single nucleotide polymorphisms in TGFB1, SOD2, XRCC1, XRCC3, APEX and ATM - a study based on DNA from formalin fixed paraffin embedded tissue samples. Int J Radiat Biol 82:577-586. doi: 10.1080/09553000600876637
28. Damaraju S, Murray D, Dufour J, Carandang D, Myrehaug S, Fallone G, Field C, Greiner R, Hanson J, Cass CE, Parliament M (2006) Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res 12:2545-2554. doi: 10.1158/ 1078-0432.CCR-05-2703
29. Merrick GS, Butler WM, Wallner KE, Murray B, Allen Z, Lief JH, Galbreath RW (2004) The effect of hormonal manipulation on urinary function following permanent prostate brachytherapy. Brachytherapy 3:22-29. doi: 10.1016/j.brachy.2003.12.001
30. Gomella LG (2007) Contemporary use of hormonal therapy in prostate cancer: Managing complications and addressing quality-of-life issues. BJU Int 99(S1):25-29. doi: 10.1111/j.1464-410X.2007.06598.x